Does the media refer more to QDEL or SMTI?

In the previous week, QuidelOrtho had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 11 mentions for QuidelOrtho and 9 mentions for Sanara MedTech. QuidelOrtho's average media sentiment score of 0.56 beat Sanara MedTech's score of 0.23 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend SMTI or AVNS?

Sanara MedTech currently has a consensus target price of $35.00, suggesting a potential upside of 2.46%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts clearly believe Sanara MedTech is more favorable than Avanos Medical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanara MedTech 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Avanos Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor SMTI or AVNS?

In the previous week, Sanara MedTech had 7 more articles in the media than Avanos Medical. MarketBeat recorded 9 mentions for Sanara MedTech and 2 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 1.16 beat Sanara MedTech's score of 0.23 indicating that Avanos Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Avanos Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, SMTI or CERS?

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $103.12M 3.04 -$37.56M -$3.77 N/A Cerus $206.13M 2.78 -$15.63M -$0.03 N/A

Is SMTI or CERS more profitable?

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 31.56% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -29.15% 31.56% 2.82% Cerus -3.06% -10.19% -3.14%

Does the media favor SMTI or CERS?

In the previous week, Sanara MedTech had 6 more articles in the media than Cerus. MarketBeat recorded 9 mentions for Sanara MedTech and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat Sanara MedTech's score of 0.23 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SMTI or OSUR?

In the previous week, Sanara MedTech had 3 more articles in the media than OraSure Technologies. MarketBeat recorded 9 mentions for Sanara MedTech and 6 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.66 beat Sanara MedTech's score of 0.23 indicating that OraSure Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral OraSure Technologies 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is RXST or SMTI more profitable?

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 31.56% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.80% -17.35% -14.70% Sanara MedTech -29.15% 31.56% 2.82%

Does the media refer more to RXST or SMTI?

In the previous week, RxSight had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 11 mentions for RxSight and 9 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.23 beat RxSight's score of 0.15 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Sanara MedTech (SMTI) Competitors

$34.10 -0.06 (-0.16%)

As of 09:32 AM Eastern

Compare

SMTI vs. QDEL, AVNS, CERS, OSUR, and RXST

Should you buy Sanara MedTech stock or one of its competitors? Sanara MedTech's main competitors and comparable companies include QuidelOrtho (QDEL), Avanos Medical (AVNS), Cerus (CERS), OraSure Technologies (OSUR), and RxSight (RXST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Sanara MedTech compare to QuidelOrtho?

QuidelOrtho (NASDAQ:QDEL) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

QuidelOrtho has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Sanara MedTech has lower revenue, but higher earnings than QuidelOrtho. Sanara MedTech is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.38	-$1.13B	-$15.41	N/A
Sanara MedTech	$103.12M	3.04	-$37.56M	-$3.77	N/A

99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 1.1% of QuidelOrtho shares are owned by insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, QuidelOrtho had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 11 mentions for QuidelOrtho and 9 mentions for Sanara MedTech. QuidelOrtho's average media sentiment score of 0.56 beat Sanara MedTech's score of 0.23 indicating that QuidelOrtho is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

QuidelOrtho presently has a consensus target price of $13.63, indicating a potential downside of 9.71%. Sanara MedTech has a consensus target price of $35.00, indicating a potential upside of 2.46%. Given Sanara MedTech's stronger consensus rating and higher probable upside, analysts clearly believe Sanara MedTech is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Sanara MedTech has a net margin of -29.15% compared to QuidelOrtho's net margin of -39.20%. Sanara MedTech's return on equity of 31.56% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
Sanara MedTech	-29.15%	31.56%	2.82%

Summary

Sanara MedTech beats QuidelOrtho on 10 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to Avanos Medical?

Sanara MedTech (NASDAQ:SMTI) and Avanos Medical (NYSE:AVNS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

In the previous week, Sanara MedTech had 7 more articles in the media than Avanos Medical. MarketBeat recorded 9 mentions for Sanara MedTech and 2 mentions for Avanos Medical. Avanos Medical's average media sentiment score of 1.16 beat Sanara MedTech's score of 0.23 indicating that Avanos Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Avanos Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sanara MedTech has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Avanos Medical has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Sanara MedTech currently has a consensus target price of $35.00, suggesting a potential upside of 2.46%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts clearly believe Sanara MedTech is more favorable than Avanos Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Avanos Medical has a net margin of -10.39% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 31.56% beat Avanos Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	31.56%	2.82%
Avanos Medical	-10.39%	5.39%	3.97%

Sanara MedTech has higher earnings, but lower revenue than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.04	-$37.56M	-$3.77	N/A
Avanos Medical	$715.90M	1.64	-$72.90M	-$1.61	N/A

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 95.2% of Avanos Medical shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by insiders. Comparatively, 2.3% of Avanos Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Sanara MedTech beats Avanos Medical on 8 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to Cerus?

Sanara MedTech (NASDAQ:SMTI) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Cerus has higher revenue and earnings than Sanara MedTech. Cerus is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.04	-$37.56M	-$3.77	N/A
Cerus	$206.13M	2.78	-$15.63M	-$0.03	N/A

In the previous week, Sanara MedTech had 6 more articles in the media than Cerus. MarketBeat recorded 9 mentions for Sanara MedTech and 3 mentions for Cerus. Cerus' average media sentiment score of 1.19 beat Sanara MedTech's score of 0.23 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by insiders. Comparatively, 5.3% of Cerus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cerus has a net margin of -3.06% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 31.56% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	31.56%	2.82%
Cerus	-3.06%	-10.19%	-3.14%

Sanara MedTech presently has a consensus target price of $35.00, indicating a potential upside of 2.46%. Cerus has a consensus target price of $4.00, indicating a potential upside of 40.85%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Sanara MedTech has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Cerus has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Summary

Cerus beats Sanara MedTech on 10 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to OraSure Technologies?

Sanara MedTech (NASDAQ:SMTI) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

In the previous week, Sanara MedTech had 3 more articles in the media than OraSure Technologies. MarketBeat recorded 9 mentions for Sanara MedTech and 6 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.66 beat Sanara MedTech's score of 0.23 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
OraSure Technologies	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Sanara MedTech has higher earnings, but lower revenue than OraSure Technologies. Sanara MedTech is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.04	-$37.56M	-$3.77	N/A
OraSure Technologies	$115.02M	2.41	-$68.73M	-$0.69	N/A

Sanara MedTech has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 4.7% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sanara MedTech presently has a consensus target price of $35.00, suggesting a potential upside of 2.46%. OraSure Technologies has a consensus target price of $3.00, suggesting a potential downside of 25.37%. Given Sanara MedTech's stronger consensus rating and higher possible upside, research analysts clearly believe Sanara MedTech is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Sanara MedTech has a net margin of -29.15% compared to OraSure Technologies' net margin of -43.70%. Sanara MedTech's return on equity of 31.56% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	31.56%	2.82%
OraSure Technologies	-43.70%	-19.09%	-16.26%

Summary

Sanara MedTech beats OraSure Technologies on 10 of the 15 factors compared between the two stocks.

How does Sanara MedTech compare to RxSight?

RxSight (NASDAQ:RXST) and Sanara MedTech (NASDAQ:SMTI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

RxSight presently has a consensus price target of $8.37, indicating a potential upside of 19.35%. Sanara MedTech has a consensus price target of $35.00, indicating a potential upside of 2.46%. Given RxSight's stronger consensus rating and higher possible upside, equities research analysts plainly believe RxSight is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 31.56% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Sanara MedTech	-29.15%	31.56%	2.82%

78.8% of RxSight shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 10.1% of RxSight shares are owned by insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

RxSight has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Sanara MedTech has lower revenue, but higher earnings than RxSight. Sanara MedTech is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	2.17	-$38.94M	-$1.13	N/A
Sanara MedTech	$103.12M	3.04	-$37.56M	-$3.77	N/A

In the previous week, RxSight had 2 more articles in the media than Sanara MedTech. MarketBeat recorded 11 mentions for RxSight and 9 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.23 beat RxSight's score of 0.15 indicating that Sanara MedTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

RxSight beats Sanara MedTech on 8 of the 15 factors compared between the two stocks.

Get Sanara MedTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMTI vs. The Competition

Export

Metric	Sanara MedTech	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$315.42M	$5.95B	$7.07B	$13.00B
Dividend Yield	N/A	1.76%	2.58%	10.72%
P/E Ratio	-9.52	26.47	269.63	25.21
Price / Sales	3.04	40.64	596.72	99.91
Price / Cash	57.74	33.59	70.53	50.75
Price / Book	50.99	5.90	13.11	6.24
Net Income	-$37.56M	$148.67M	$3.45B	$347.70M
7 Day Performance	0.18%	1.86%	0.78%	0.87%
1 Month Performance	45.67%	4.64%	1.45%	0.90%
1 Year Performance	12.37%	8.94%	67.07%	20.13%

Sanara MedTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMTI Sanara MedTech	1.5882 of 5 stars	$34.11 -0.2%	$35.00 +2.6%	+7.0%	$313.46M	$103.12M	N/A	60	Earnings Report Analyst Upgrade Short Interest Decrease
QDEL QuidelOrtho	1.5287 of 5 stars	$17.38 -1.2%	$13.63 -21.6%	-44.3%	$1.18B	$2.73B	N/A	6,500	Analyst Downgrade
AVNS Avanos Medical	1.3225 of 5 stars	$24.99 flat	N/A	N/A	$1.17B	$715.90M	N/A	2,287
CERS Cerus	2.1132 of 5 stars	$2.25 +2.5%	$4.00 +78.2%	+113.5%	$450.40M	$206.13M	N/A	290
OSUR OraSure Technologies	1.8296 of 5 stars	$4.13 -1.1%	$3.00 -27.3%	+41.1%	$284.01M	$115.02M	N/A	840

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMTI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanara MedTech (SMTI) Competitors

SMTI vs. QDEL, AVNS, CERS, OSUR, and RXST

How does Sanara MedTech compare to QuidelOrtho?

Summary

How does Sanara MedTech compare to Avanos Medical?

Summary

How does Sanara MedTech compare to Cerus?

Summary

How does Sanara MedTech compare to OraSure Technologies?

Summary

How does Sanara MedTech compare to RxSight?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sanara MedTech (SMTI) Competitors

SMTI vs. QDEL, AVNS, CERS, OSUR, and RXST

How does Sanara MedTech compare to QuidelOrtho?

Which has more risk & volatility, QDEL or SMTI?

Which has stronger valuation and earnings, QDEL or SMTI?

Do institutionals & insiders believe in QDEL or SMTI?

Does the media refer more to QDEL or SMTI?

Do analysts rate QDEL or SMTI?

Is QDEL or SMTI more profitable?

Summary

How does Sanara MedTech compare to Avanos Medical?

Does the media favor SMTI or AVNS?

Which has more volatility and risk, SMTI or AVNS?

Do analysts recommend SMTI or AVNS?

Is SMTI or AVNS more profitable?

Which has better earnings & valuation, SMTI or AVNS?

Do insiders and institutionals hold more shares of SMTI or AVNS?

Summary

How does Sanara MedTech compare to Cerus?

Which has better earnings & valuation, SMTI or CERS?

Does the media favor SMTI or CERS?

Do institutionals & insiders believe in SMTI or CERS?

Is SMTI or CERS more profitable?

Do analysts prefer SMTI or CERS?

Which has more risk and volatility, SMTI or CERS?

Summary

How does Sanara MedTech compare to OraSure Technologies?

Does the media favor SMTI or OSUR?

Which has higher valuation & earnings, SMTI or OSUR?

Which has more volatility and risk, SMTI or OSUR?

Do insiders and institutionals have more ownership in SMTI or OSUR?

Do analysts recommend SMTI or OSUR?

Is SMTI or OSUR more profitable?

Summary

How does Sanara MedTech compare to RxSight?

Do analysts recommend RXST or SMTI?

Is RXST or SMTI more profitable?

Do insiders & institutionals believe in RXST or SMTI?

Which has more risk & volatility, RXST or SMTI?

Which has better earnings and valuation, RXST or SMTI?

Does the media refer more to RXST or SMTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools